By engaging the STING pathway, the drug promotes type-I interferon secretion, up-regulates MHC-I/II, and re-programs the tumor microenvironment toward a CD8+ T-cell- and M1 macrophage-dominant phenotype while suppressing M2 macrophages (90, 91). Here, CD8A is linked to neoplasm.